This article considers whether Eli Lilly, at around US$927 per share, is still priced for opportunity or already reflects ...
Eli Lilly remains well-positioned in the obesity treatment market despite early script underperformance of Foundayo. Read ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results